Business

PMV Pharma raises USD 50.8m to fund rezatapopt NDA submission in Q1 2027

Edited by Robert McTiernan··2 min read
PMV Pharma raises USD 50.8m to fund rezatapopt NDA submission in Q1 2027

Princeton, New Jersey-based PMV Pharmaceuticals (Nasdaq: PMVP) announced an oversubscribed public offering expected to raise approximately USD 50.8 million in gross proceeds as it advances rezatapopt (PC14586), its lead mutant p53 reactivator, toward a planned New Drug Application (NDA) submission in Q1 2027 for platinum-resistant or refractory ovarian cancer harboring a TP53 Y220C mutation.

The financing includes common stock, pre-funded warrants, and accompanying warrants that could result in substantial additional dilution if exercised. PMV held USD 79.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026, with existing resources expected to fund operations through Q2 2027. The new capital provides an additional buffer around the planned NDA filing, although the company has not yet updated its formal runway guidance.

Rezatapopt is a first-in-class small molecule designed to selectively bind and stabilize the thermally destabilized p53 Y220C mutant protein, restoring wild-type-like tumor suppressor activity. The compound is being evaluated in the Phase II pivotal PYNNACLE trial, a registrational basket study in advanced solid tumors harboring TP53 Y220C mutations.

Updated interim data disclosed ahead of the financing showed a 46% overall response rate among 76 evaluable patients with platinum-resistant or refractory ovarian cancer, including four confirmed complete responses and 29 confirmed partial responses. Median duration of response was 10.0 months, extending the earlier dataset based on 48 evaluable patients.

The AllSci BriefSystematic R&D and deal news. Daily.

PMV said a recent interaction with the US FDA supports its strategy to seek accelerated approval, with an NDA submission planned in Q1 2027. The FDA has granted rezatapopt Fast Track designation for locally advanced or metastatic solid tumors with a p53 Y220C mutation and Orphan Drug Designation for TP53 Y220C-positive ovarian, fallopian tube, and primary peritoneal cancers.

PMV is also working with Foundation Medicine, a Roche subsidiary, to develop FoundationOne CDx as a companion diagnostic to identify patients with TP53 Y220C-positive tumors.

TP53 mutations occur in approximately half of human cancers, although the Y220C variant represents a much smaller genetically defined subset. No approved therapy currently directly targets mutant p53, leaving rezatapopt without a direct marketed comparator.

Spot something wrong? Report an issue with this article